Is Tempest Therapeutics Inc (TPST) overvalued? · $26.3M cap
Tempest Therapeutics Inc (TPST) is a biotechnology company listed on US.
This page asks whether Tempest Therapeutics Inc (TPST) looks expensive on cached numbers — not a short thesis.
No cached income statement for TPST, so there is no earnings base to call rich or cheap.
TPST currently screens at market cap $26.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TPST 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TPST stock page for the full model, not this heading.
Not investment advice.